Oxford University today began gathering volunteers to conduct clinical trials of Phase II and III for the Covid-19 experimental vaccine it is developing in collaboration with AstraZeneca.
Phase I clinical trials of healthy volunteers began in April. The vaccination of 1,000 volunteers has been completed and their course is being monitored.
Tests on 10,260 adults and children
Phase II of the clinical trials will include 10,260 adults and children and will specifically include adults aged 56 to 69, adults over 70 and children aged 5 to 12 and aims to evaluate the effectiveness of the vaccine in people of different ages and ways. with which the immune system responds to older people and children.
Phase III aims to evaluate the effectiveness of the vaccine in a large number of people over the age of 18.
The vaccine, called ChAdOx1 nCoV-19, is based on a weakened version of a common cold adenovirus (ChAdOx1) that infects chimpanzees and has been genetically modified to make it impossible to infect humans. Protein droplets (S) from the SARS-CoV-2 virus were added to the ChAdOx1 complex. This protein is found on the surface of the new colon and plays an important role in infection. SARS-CoV-2 uses the protein pin to attach to the ACE2 receptors in human cells to achieve its entry into cells and cause infection.
By vaccinating with ChAdOx1 nCoV-19, we hope to make the body recognize and develop an immune response to the protein spike, which will help prevent SARS-CoV-2 from entering cells and prevent infection, the statement said. University of Oxford. (https://bit.ly/2XhETwM)
“Clinical trials are going very well”
“Clinical trials are evolving very well and we are now launching research to evaluate how effectively the vaccine elicits an immune response in older adults and to test whether it is able to provide protection for the general population,” said Professor Andrew Pollard. Oxford Vaccine Group.
For her part, Mene Pangalos, Executive Vice President of AstraZeneca, said: “We will do everything possible to work with governments, international organizations and partners around the world to increase production and distribution and ensure a speedy, fair and equal distribution of an accessible vaccine ”.